Last updated: April 23, 2026
Who Supplies the Inputs for MODEYSO (and What Parts of the Value Chain Matter in Patents and GMP)
No structured, verifiable supplier or manufacturer list for “MODEYSO” can be produced from the information provided. Without a confirmed drug identity (generic name, strength, dosage form) and an authoritative regulatory record tying that identity to specific facilities and upstream material sources, any supplier attribution would be speculative.
What exactly is “MODEYSO” in regulatory terms?
A supplier map for a pharmaceutical requires at least one of the following identifiers tied to the marketed product:
- USAN/INN generic name and dosage form (tablet, capsule, solution, injection)
- Strength (mg per unit)
- Marketing authorization record (NDA/BLA/ANDA or EMA marketing authorization)
- Local label pack data (manufacturer and distributor names)
- Drug Master File (DMF) cross-references for key excipients/actives
“MODEYSO” alone does not establish a single, defensible product identity.
Which supplier categories are relevant for drug development and patent strategy?
For any confirmed product identity, suppliers typically split into:
- API (active pharmaceutical ingredient)
- API manufacturer(s)
- API intermediate supplier(s) where covered by upstream process patents
- Formulation and drug product
- Oral solid or sterile fill-finish manufacturer(s)
- Packaging and secondary labeling vendors
- Critical inputs
- Excipients with DMF-controlled sourcing
- Specialized reagents for manufacture (if disclosed in DMFs or regulatory reviews)
- Regulatory and quality chain
- QA release testing labs
- Stability testing facilities
- Contract organizations handling GMP batch record execution
A complete and accurate supplier list must tie these categories to the same confirmed product record.
How supplier identification is sourced in defensible patents and GMP filings
A supplier list is typically derived from one or more of:
- Regulatory label (manufacturer, MAH, packager)
- FDA Orange Book (application references and manufacturing sites when available)
- FDA NDA/ANDA review documents (CMC sections; listed facilities and suppliers)
- EU product register (authorized manufacturing sites per marketing authorization)
- DMF references in approved applications (excipient and sometimes API components)
- Patent prosecution and assignments that identify manufacturing process inventors and licensors
None of these can be reliably executed for “MODEYSO” without a confirmed product identity.
Key Takeaways
- A supplier list for “MODEYSO” cannot be generated accurately from the provided information.
- Supplier attribution must be anchored to a confirmed generic identity and an official regulatory record that links facilities to batches and labels.
- Once the product identity is fixed, supplier mapping can cover API, drug product, fill-finish, excipients, and QA release testing using Orange Book, marketing authorization registers, label text, and CMC/DMF cross-references.
FAQs
-
What is required to identify MODEYSO suppliers reliably?
A confirmed product identity (generic name, dosage form, strength) tied to a specific approved application or marketing authorization record.
-
Do suppliers include both API and drug-product manufacturers?
Yes. A defensible supplier map separates API manufacture from drug product manufacture (and often fill-finish for injectables).
-
Are excipients included in supplier lists?
Yes, when excipients are DMF-controlled or when regulatory filings disclose the sourcing/manufacturing facilities.
-
Can supplier names come from patent documents alone?
Sometimes, but patents rarely provide complete GMP sourcing. They usually need to be corroborated with label, regulatory reviews, or DMF references.
-
Why can’t the supplier list be inferred from the brand name?
Brand names alone do not uniquely determine the generic product, strength, dosage form, or approved manufacturing network.
References
[1] FDA. “NDA/ANDA Application & Approval Information.” FDA.gov.
[2] FDA. “Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.” FDA.gov.
[3] EMA. “EU Medicines Register.” European Medicines Agency.
